[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053808":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":64,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":26,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":92,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Suez Canal University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Norepinephrine Group","EXPERIMENTAL","Participants will receive continuous norepinephrine infusion at a fixed dose of 0.03 µg\u002Fkg\u002Fmin initiated immediately after induction of anesthesia and continued until skin closure within a protocolized hemodynamic management strategy.",[13],"Drug: Norepinephrine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","PLACEBO_COMPARATOR","Participants will receive an equivalent volume normal saline infusion initiated immediately after induction of anesthesia and continued until skin closure within the same protocolized hemodynamic management strategy.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Norepinephrine","Continuous norepinephrine infusion administered at a fixed dose of 0.03 µg\u002Fkg\u002Fmin from induction of anesthesia until skin closure.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Equivalent volume normal saline infusion administered from induction of anesthesia until skin closure at the same infusion rate as the active intervention to maintain blinding within a protocolized hemodynamic management strategy.",[15],[32,37],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Mohammad Elhossieny Salama, MD","CONTACT","+201016865861","MohammadElhossieny88@med.suez.edu.eg",{"name":38,"role":34,"phone":39,"phoneExt":26,"email":40},"Mahmoud Hosny Ahmed, MD","+201097920831","M.hosnawy@med.suez.edu.eg",[42],{"facility":43,"status":26,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Suez Canal University Hospitals","Ismailia","Ismailia Governorate","41522","Egypt","EG",{"type":50,"coordinates":51},"Point",[52,53],32.27225,30.60427,{"lat":53,"lon":52},[56,60,62],{"name":57,"role":34,"phone":58,"phoneExt":26,"email":59},"Muhammad Elhossieny Salama, MD","01016865861","mohammadelhossieny88@med.suez.edu.eg",{"name":57,"role":61,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":38,"role":63,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100053808","pro-stress-trial-proactive-low-dose-norepinephrine-to-reduce-intraoperative-fluid-administration-in-patients-at-high-risk-for-postoperative-pulmonary-complications-undergoing-laparoscopic-abdominal-surgery-100053808",false,"NCT07627360","PRO STRESS Trial: Proactive Low-Dose Norepinephrine to Reduce Intraoperative Fluid Administration in Patients at High-Risk for Postoperative Pulmonary Complications Undergoing Laparoscopic Abdominal Surgery","Proactive Low-Dose Norepinephrine to Reduce Intraoperative Fluid Administration in Patients at High-Risk for Postoperative Pulmonary Complications Undergoing Laparoscopic Abdominal Surgery: A Randomized Controlled Trial","PRO STRESS","Inclusion Criteria:\n\n* Adult patients aged 18 years or older.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled for elective laparoscopic major abdominal surgery under general anesthesia with an expected duration greater than 2 hours.\n* Patients with ARISCAT score ≥ 45 indicating high risk for postoperative pulmonary complications.\n\nExclusion Criteria:\n\n* Known hypersensitivity to norepinephrine.\n* Severe left ventricular dysfunction with ejection fraction \\\u003C 35%.\n* Significant cardiac arrhythmia.\n* Uncontrolled hypertension defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg.\n* End-stage renal disease.\n* Requirement for vasopressor support before induction of anesthesia.\n* Emergency surgery.","ALL","18 Years",{"count":77,"type":78},130,"ESTIMATED","INTERVENTIONAL",[81],"NA","Intraoperative hypotension is commonly treated with fluid administration; however, excessive fluid therapy may contribute to postoperative pulmonary complications. This randomized double-blind controlled trial evaluates whether proactive administration of fixed low-dose norepinephrine reduces intraoperative crystalloid administration while maintaining hemodynamic stability in high-risk patients undergoing laparoscopic abdominal surgery. One hundred and thirty patients will be randomized to receive either norepinephrine infusion (0.03 µg\u002Fkg\u002Fmin) or placebo from induction until skin closure within a protocolized hemodynamic strategy guided by mean arterial pressure and pulse pressure variation.",[84,85,86],"Intraoperative Hypotension","Postoperative Pulmonary Complications (PPCs)","Fluid Over-load",[23,88,89,90,91],"Fluid Therapy","Pulmonary Complications","Abdominal Surgery","Vasopressor","NOT_YET_RECRUITING","2026-07-10",{"date":95,"type":96},"2026-07-13","ACTUAL",{"date":98,"type":78},"2026-07-15",{"date":100,"type":78},"2026-11",{"name":5,"class":6},1]